Tourmaline Bio, Inc. (TRML)
Data as of , from SEC Form 4 filings.
No open-market insider trades (90d)Watch TRML
See up to 3 months of TRML. The 7-day demo opens the 1M and 3M ranges and puts TRML on your watchlist.
Start 7-day demoLatest TRML insider trades
About Tourmaline Bio, Inc. (TRML)
Tourmaline Bio, Inc. is an SEC registrant, filing under CIK 0001827506, classified as biological products (no diagnostic substances). It is grouped with Health Care companies on this site.
TRML Form 4 activity by transaction type, last 90 days
No Form 4 activity for TRML in the last 90 days.
TRML insider transactions (Form 4)
6519 Form 4 filings on record, the earliest from Jun 4, 2025, newest first.
| Traded | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Ryan F. Robinson - Officer | Derivative | Employee Stock Option (Right to Buy) | 76,400 | - footnote F3 | - | |
| Ryan F. Robinson - Officer | Derivative | Employee Stock Option (Right to Buy) | 58,000 | - footnote F3 | - | |
| Ryan F. Robinson - Officer | Other | Common Stock | 14,366 | - footnote F2 | - | |
| Ryan F. Robinson - Officer | Derivative | Employee Stock Option (Right to Buy) | 25,845 | - footnote F3 | - | |
| Ryan F. Robinson - Officer | Derivative | Employee Stock Option (Right to Buy) | 16,000 | - footnote F3 | - | |
| ||||||
| Parvinder Thiara | Derivative | Employee Stock Option (Right to Buy) | 10,000 | - footnote F3 | - | |
| Parvinder Thiara | Derivative | Employee Stock Option (Right to Buy) | 10,000 | - footnote F3 | - | |
| Parvinder Thiara | Derivative | Employee Stock Option (Right to Buy) | 16,800 | - footnote F3 | - | |
| Parvinder Thiara | Other | Common Stock | 83,782 | - footnote F2 | - | |
| ||||||
| Susan Dana Jones - Officer | Derivative | Employee Stock Option (Right to Buy) | 46,774 | - footnote F4 | - | |
| Susan Dana Jones - Officer | Derivative | Employee Stock Option (Right to Buy) | 58,000 | - footnote F4 | - | |
| Susan Dana Jones - Officer | Other | Common Stock | 19,782 | - footnote F2 | - | |
| Susan Dana Jones - Officer | Derivative | Common Stock | 3,152 | - footnote F3 | - | |
| Susan Dana Jones - Officer | Derivative | Employee Stock Option (Right to Buy) | 76,219 | - footnote F4 | - | |
| ||||||
| Kevin Bruce Johnson - Officer | Derivative | Employee Stock Option (Right to Buy) | 58,000 | - footnote F4 | - | |
| Kevin Bruce Johnson - Officer | Other | Common Stock | 40,538 | - footnote F2 | - | |
| Kevin Bruce Johnson - Officer | Derivative | Common Stock | 11,046 | - footnote F3 | - | |
| Kevin Bruce Johnson - Officer | Derivative | Employee Stock Option (Right to Buy) | 96,146 | - footnote F4 | - | |
| Kevin Bruce Johnson - Officer | Derivative | Employee Stock Option (Right to Buy) | 46,774 | - footnote F4 | - | |
| ||||||
| Sandeep Chidambar Kulkarni - Officer | Derivative | Common Stock | 30,387 | - footnote F3 | - | |
| Sandeep Chidambar Kulkarni - Officer | Other | Common Stock | 7,000 | - footnote F2 | - | |
| Sandeep Chidambar Kulkarni - Officer | Derivative | Employee Stock Option (Right to Buy) | 503,478 | - footnote F5 | - | |
| Sandeep Chidambar Kulkarni - Officer | Derivative | Employee Stock Option (Right to Buy) | 254,207 | - footnote F5 | - | |
| Sandeep Chidambar Kulkarni - Officer | Derivative | Employee Stock Option (Right to Buy) | 226,000 | - footnote F5 | - | |
| Sandeep Chidambar Kulkarni - Officer | Other | Common Stock | 724,664 | - footnote F2 | - | |
| ||||||
| Aaron Kantoff | Derivative | Employee Stock Option (Right to Buy) | 10,000 | - footnote F3 | - | |
| Aaron Kantoff | Derivative | Employee Stock Option (Right to Buy) | 16,800 | - footnote F3 | - | |
| Aaron Kantoff | Other | Common Stock | 88,281 | - footnote F2 | - | |
| ||||||
| Sapna Srivastava | Derivative | Employee Stock Option (Right to Buy) | 10,000 | - footnote F3 | - | |
| Sapna Srivastava | Derivative | Employee Stock Option (Right to Buy) | 16,800 | - footnote F3 | - | |
| Sapna Srivastava | Other | Common Stock | 518 | - footnote F2 | - | |
| Sapna Srivastava | Derivative | Employee Stock Option (Right to Buy) | 20,000 | - footnote F3 | - | |
| ||||||
| Caley Castelein | Derivative | Employee Stock Option (Right to Buy) | 10,000 | - footnote F4 | - | |
| Caley Castelein | Derivative | Employee Stock Option (Right to Buy) | 16,800 | - footnote F4 | - | |
| Caley Castelein | Other | Common Stock | 515,997 | - footnote F2 | - | |
| Caley Castelein | Other | Common Stock | 431,939 | - footnote F2 | - | |
| Caley Castelein | Derivative | Employee Stock Option (Right to Buy) | 10,000 | - footnote F4 | - | |
| ||||||
| Mark McDade | Derivative | Employee Stock Option (Right to Buy) | 20,000 | - footnote F6 | - | |
| Mark McDade | Derivative | Employee Stock Option (Right to Buy) | 10,000 | - footnote F6 | - | |
| Mark McDade | Derivative | Employee Stock Option (Right to Buy) | 16,800 | - footnote F6 | - | |
| Mark McDade | Other | Common Stock | 518 | - footnote F2 | - | |
| Mark McDade | Other | Common Stock | 183,177 | - footnote F2 | - | |
| Mark McDade | Other | Common Stock | 110,083 | - footnote F2 | - | |
| Mark McDade | Other | Common Stock | 448,431 | - footnote F2 | - | |
| ||||||
| W. Bradford Middlekauff - Officer | Other | Common Stock | 60,988 | - footnote F2 | - | |
| W. Bradford Middlekauff - Officer | Derivative | Common Stock | 8,213 | - footnote F3 | - | |
| W. Bradford Middlekauff - Officer | Derivative | Employee Stock Option (Right to Buy) | 124,991 | - footnote F4 | - | |
| W. Bradford Middlekauff - Officer | Derivative | Employee Stock Option (Right to Buy) | 46,774 | - footnote F4 | - | |
| W. Bradford Middlekauff - Officer | Derivative | Employee Stock Option (Right to Buy) | 58,000 | - footnote F4 | - | |
| ||||||
 Clay B. Siegall | Derivative | Employee Stock Option (Right to Buy) | 15,000 | - footnote F2 | - | |
| Clay B. Siegall | Derivative | Employee Stock Option (Right to Buy) | 16,800 | - footnote F2 | - | |
| Clay B. Siegall | Derivative | Employee Stock Option (Right to Buy) | 20,000 | - footnote F2 | - | |
| ||||||
| Ryan F. Robinson - Officer | Option exercise | Common Stock | 14,366 | $13.92 | $200K | |
| Ryan F. Robinson - Officer | Option exercise | Employee Stock Option (Right to Buy) | 14,366 | $0.00 | - | |
| Sandeep Chidambar Kulkarni - Officer | Option exercise | Common Stock | 25,316 | $7.90 | $200K | |
| Sandeep Chidambar Kulkarni - Officer | Option exercise | Employee Stock Option (Right to Buy) | 25,316 | $0.00 | - | |
| Aaron Kantoff | Gift | Common Stock | 5,000 | $0.00 | - | |
| Kevin Bruce Johnson - Officer | Gift | Common Stock | 6,250 | $0.00 | - | |
| Caley Castelein | Gift | Common Stock | 522 | $0.00 | - | |
| Aaron Kantoff | Option exercise | Common Stock | 37,890 | $0.13 | $5K | |
| Aaron Kantoff | Option exercise | Common Stock | 10,000 | $9.46 | $95K | |
| Aaron Kantoff | Option exercise | Stock Option (Right to Buy) | 37,890 | $0.00 | - | |
| Aaron Kantoff | Option exercise | Stock Option (Right to Buy) | 10,000 | $0.00 | - | |
| Mark McDade - Director | Grant or award | Stock Option (Right to Buy) | 16,800 | $0.00 | - | |
| Clay B. Siegall - Director | Grant or award | Stock Option (Right to Buy) | 16,800 | $0.00 | - | |
TRML insider trading FAQ
What is the latest insider trade for TRML?
Tourmaline Bio, Inc. (TRML) has filed no insider reports in the last 90 days. The most recent on record is dated 28 October 2025. The full record for TRML runs to 19 Form 4 filings, the earliest from 4 June 2025. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying TRML stock?
No insider purchases of TRML were filed in the last 90 days.
How many insiders are selling TRML stock?
No insider sales of TRML were filed in the last 90 days.
Where can I see TRML SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects TRML Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Ryan F. Robinson view on EDGAR
- - Parvinder Thiara view on EDGAR
- - Susan Dana Jones view on EDGAR
- - Kevin Bruce Johnson view on EDGAR
- - Sandeep Chidambar Kulkarni view on EDGAR
- - Aaron Kantoff view on EDGAR
- - Sapna Srivastava view on EDGAR
- - Caley Castelein view on EDGAR
- - Mark McDade view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where TRML's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow TRML with a 7-day demo
- TRML on your watchlist
- Every TRML Form 4 filing on record
- Up to 3 months of TRML price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
